Phase III Randomized, Double-Blind Study of Prednisone for Duchenne Muscular Dystrophy
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Characterize the effect of prednisone on muscle protein metabolism in patients
with Duchenne muscular dystrophy.
II. Determine whether prednisone changes levels of insulin-like growth factor 1, growth
hormone, and insulin.
III. Characterize the effect of prednisone on muscle morphometry and muscle localization of
utrophin.
IV. Compare the prednisone response in patients with Duchenne muscular dystrophy to that seen
in normal individuals and in patients with facioscapulohumeral dystrophy.
Phase:
Phase 3
Details
Lead Sponsor:
National Center for Research Resources (NCRR)
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS) University of Rochester